- Scientists at a university now study how cells send signals.
- Cells use networks of proteins to sense their environment.
- One important protein called mTOR controls different cell tasks.
- mTOR works as two parts that do different jobs.
- Many drugs stop both parts of mTOR at the same time.
- Stopping one part can make cancer cells more resistant to treatment.
- The new study shows we could block only one part.
- This idea may help scientists design better cancer drugs in future.
Difficult words
- scientist — A person who studies and does research about natureScientists
- signal — A sign or message from one thing to anothersignals
- protein — A molecule in cells that does many jobsproteins
- resistant — Not easily affected by a drug or change
- treatment — Medical care to try to cure or help
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you like to learn about cells and proteins?
- Which would you prefer: a medicine that blocks one part or both parts?
- Have you learned about proteins at school?
Related articles
New modular CAR-T system controls where and when cells attack
Researchers at the University of Chicago created GA1CAR, a modular CAR-T system that uses short-lived Fab fragments to guide and pause tumor targeting. In animal tests the same cells were redirected to different tumors and remained functional.
New oral Listeria vaccine shows promise against colorectal cancer
Researchers report a modified oral vaccine made from Listeria that primes immune cells in the gut and limits tumor growth in mice. The vaccine worked best when combined with immune checkpoint inhibitors and caused few side effects.
New device measures blood viscosity in real time
Researchers at the University of Missouri created a non-invasive device that monitors blood viscosity and density in real time using ultrasound and software. It can read blood without drawing samples and may help in diseases like sickle cell.
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.